Urine Glycosaminoglycan Scores for Surveillance of Recurrence in Intermediate- and High-risk Nonmetastatic Clear Cell Renal Cell Carcinoma-An Observational Prospective Multicentre Diagnostic Test Cohort Study [0.03%]
中高危未转移肾透明细胞癌复发监测中的尿糖胺聚糖评分：一项观察性前瞻性多中心诊断试验队列研究
Saeed Dabestani,Nessn H Azawi,Riccardo Campi et al.
Saeed Dabestani et al.
Background and objective: Nonmetastatic (M0) clear cell renal cell carcinoma (ccRCC) recurs in ∼20% of patients within 5 yr after surgery. With no biomarkers available, recurrence detection relies on radiological imaging...
A Deep Prostate-specific Antigen Response to Darolutamide plus Androgen Deprivation Therapy Is Associated with Better Clinical Outcomes in the Phase 3 ARANOTE Trial in Patients with Metastatic Hormone-sensitive Prostate Cancer [0.03%]
III期ARANOTE试验：达罗特胺联合雄激素剥夺治疗取得深度前列腺特异性抗原应答与转移性激素敏感型前列腺癌患者的更好临床结局相关
Fred Saad,Alberto Briganti,Kunhi Parambath Haresh et al.
Fred Saad et al.
Background and objective: Darolutamide plus androgen deprivation therapy (ADT) significantly improved radiological progression-free survival (rPFS) versus ADT in ARANOTE (NCT04736199). Here we report prostate-specific ant...
Prevalence of Kidney Cancer in Attendees for Combined Lung and Kidney Cancer Screening by Computed Tomography Scanning [0.03%]
受试者接受计算机断层扫描联合筛查肺部和肾脏癌症中肾癌的发病率
Sabrina H Rossi,Jessica Kitt,Angela Godoy et al.
Sabrina H Rossi et al.
Kidney cancer (KC) screening may be facilitated by targeting individuals at a higher risk and combining with other screening programmes. Previous estimates of the prevalence of screen-detected KC are outdated and do not enable an accurate a...
Development of a Health-related Quality of Life Questionnaire for Patients with Metastatic or Localized Renal Cell Carcinoma [0.03%]
开发用于转移性或局部肾细胞癌患者的健康相关生活质量问卷
Cristiane D Bergerot,David Cella,Paulo G Bergerot et al.
Cristiane D Bergerot et al.
Background and objective: Despite significant advances in treatments for renal cell carcinoma (RCC) over the past decade, health-related quality of life (HRQOL) assessments have not been updated to reflect these developme...
Challenges in Follow-up After Kidney-sparing Surgery for Upper Tract Urothelial Carcinoma: Insights from a Delphi Consensus [0.03%]
保肾手术治疗上尿路尿路上皮癌术后随访的挑战：德尔菲共识的启示
Orlane Figaroa,Hugo Schuil,Guido Kamphuis et al.
Orlane Figaroa et al.
Background and objective: Kidney-sparing surgery (KSS) is the preferred treatment for patients with low-risk upper tract urothelial carcinoma (UTUC), offering a balance between oncologic efficacy and renal preservation. H...
Reply to Hatice Bolek's Letter to the Editor re: Hilin Yildirim, Katja K.H. Aben, Maarten J. Bijlsma, et al. A Nationwide Real-world Evaluation of Upfront Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma in the Immunotherapy Era. Eur Urol Oncol 2025;8:623-31 [0.03%]
对Hatice Bolek关于Hilin Yildirim，Katja K.H.Aben，Maarten J.Bijlsma等人的来信答复。这些患者患有同步转移性肾细胞癌，在免疫治疗时代前期进行根治性肾切除术的全国真实世界评估。 Eur Urol Oncol 2025;8:623-31
Hilin Yildirim,Adriaan D Bins,Axel Bex et al.
Hilin Yildirim et al.
Re: Hilin Yildirim, Katja K.H. Aben, Maarten J. Bijlsma, et al. A Nationwide Real-world Evaluation of Upfront Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma in the Immunotherapy Era. Eur Urol Oncol 2025;8:623-31 [0.03%]
免疫治疗时代下同步转移性肾细胞癌患者前期 cytoreductive nephrectomy的全国真实世界评估答复：Hilin Yildirim，Katja K.H. Aben，Maarten J. Bijlsma等
Hatice Bolek
Hatice Bolek
The Evolving Landscape of Systemic Immunotherapy for Bacillus Calmette-Guérin-naïve High-risk Non-muscle-invasive Bladder Cancer: At the Edge of a Tsunami? [0.03%]
从零开始的系统免疫疗法治疗卡介苗初治高危非肌层浸润性膀胱癌：巨浪来袭？
Pierre-Etienne Gabriel,Mathieu Roumiguié,Gautier Marcq et al.
Pierre-Etienne Gabriel et al.
Background and objective: Treatment options for high-risk (HR) non-muscle-invasive bladder cancer (NMIBC) are still limited. The addition of systemic immunotherapy to intravesical bacillus Calmette-Guérin (BCG) instillat...
Outcomes for [177Lu]Lu-PSMA-617 with and Without Concurrent Use of Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration-resistant Prostate Cancer [0.03%]
[177Lu]Lu-PSMA-617单药或联合使用雄激素受体通路抑制剂治疗转移性去势抵抗性前列腺癌的疗效及安全性：一项前瞻性、多中心研究
Miguel Muniz,Oliver Sartor,Jacob J Orme et al.
Miguel Muniz et al.
Background and objective: Large clinical trials, including VISION, have established the safety of combining [177Lu]Lu-PSMA-617 with an androgen receptor pathway inhibitor (ARPI). Most patients receiving [177Lu]Lu-PSMA-617...